<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428242</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-202</org_study_id>
    <nct_id>NCT04428242</nct_id>
  </id_info>
  <brief_title>Study Evaluating Retinal Health Monitoring System Thickness Module</brief_title>
  <official_title>Evaluation of the Retinal Health Monitoring System - Retinal Thickness Module in Subjects With Normal Macular Thickness and Subjects With Center-involving Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kubota Vision Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kubota Vision Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness
      Module (RHMS - RTM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the Retinal Health Monitoring System - Retinal Thickness Module in subjects
      with normal macular thickness and subjects with center-involving macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    COVD-19
  </why_stopped>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the RHMS-RTM retinal thickness measurements</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the ability of the RHMS-RTM device to measure retinal thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RHMS-RTM repeatability</measure>
    <time_frame>1 day</time_frame>
    <description>To assess repeatability of the RHMS-RTM device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of retinal thickness measurements between the RHMS-RTM and the SD-OCT</measure>
    <time_frame>1 month</time_frame>
    <description>To evaluate the agreement of measurements by the RHMS-RTM and SD-OCT</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Macular Edema</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Subjects with normal macular thickness in one or both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Subjects with center-involving macular edema due to w/AMD in one or both eyes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Subjects with center-involving macular edema due to DR or RVO in one or both eyes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RHMS-RTM</intervention_name>
    <description>Assessment of retinal thickness.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Handheld swept source (SS) optical coherence tomography (OCT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SD-OCT</intervention_name>
    <description>Assessment of retinal structure.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged ≥ 18 years old with normal macular thickness, center-involving macular edema
        due to wAMD, diabetic retinopathy or retinal vein occlusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Corrected visual acuity (VA) of 20/100 or better, in the study eye(s)

          2. Media clarity, undilated pupil size, OCT-B scans, axial length measurements in the
             study eye(s)

          3. Able to perform self-testing of retinal thickness with the RHMS-RTM after training

          4. Able and willing to give informed consent

          5. Group 1:

               1. Macula with normal thickness [central subfield thickness (CST) below 305 microns
                  as measured by SD-OCT] in at least one eye

               2. Patients with dry AMD are eligible for enrollment into Group 1

               3. No history of wet AMD, DR, or RVO in either eye

          6. Group 2 and Group 3 (in at least one or the same eye):

               1. History of center-involving macular edema due to wet AMD (Group 2); or DR or RVO
                  (Group 3)

               2. Macular edema on SD-OCT with CST ≥ 305 microns

        Exclusion Criteria:

          1. History of corneal refractive surgery, photorefractive keratectomy, radial keratotomy,
             in the study eye

          2. History of epiretinal membrane, vitreomacular traction, or macular hole in the study
             eye(s)

          3. Participation in any study using an investigational drug within 30 days or screening
             or investigational device within 60 days of screening

          4. Refractive error: spherical equivalent of &gt; 3 diopters of hyperopia or &gt; 6 diopters of
             myopia, or &gt; 2 diopters cylinder in the study eye(s)

          5. History of photocoagulation laser scar or other retinal scar in the central 3 mm of
             the macula, in the study eye(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Gregory, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kubota Vision Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group, Inc</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema, Wet AMD</keyword>
  <keyword>Retinal Thickness</keyword>
  <keyword>Diabetic Retinopathy, Retinal Vein Occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

